{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T07:39:46Z","timestamp":1779176386633,"version":"3.51.4"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Royal Library, Copenhagen University Library"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Unspecific symptoms of anxiety and distress are frequently encountered in patients in both general practice and acute psychiatric services. Minor tranquillizers may be a treatment option when non-pharmacological interventions are insufficient or unavailable. We conducted a systematic review with network meta-analysis of the evidence for short-term (1\u20134\u00a0weeks) pharmacological treatment of newly onset symptoms of anxiety and distress. We searched the PsycInfo, MEDLINE, EMBASE and Cochrane Library databases and extracted data following a predefined hierarchy of outcomes. We assessed risk of bias using the Cochrane Risk of Bias tool and the certainty of the evidence using the Grading of Recommendations Assessment, Development and Evaluation framework (GRADE). We included 34 randomized trials comprising a total of 7044 patients with adjustment disorders or anxiety spectrum disorders. The network meta-analysis showed that regarding the critical outcome symptoms of anxiety within 1\u20134\u00a0weeks benzodiazepines (SMD \u2212 0.58, 95% CI \u2212 0.77 to \u2212 0.40), quetiapine (SMD \u2212 0.51, 95% CI \u2212 0.90 to \u2212 0.13) and pregabalin (SMD \u2212 0.58, 95% CI \u2212 0.87 to \u2212 0.28) all performed better than placebo with no statistically significant difference between the drugs. Data on other important outcomes were inconsistently reported. Adverse effects varied, but overall, it was uncertain whether adverse effects differed between interventions. The evidence regarding the risk of dependence was uncertain, but dependence may be a concern in susceptible individuals even with short-term treatment. Overall, the certainty of the evidence according to GRADE was rated as low to very low across outcomes. Despite the limitations in the evidence, the results of this review can inform treatment guidelines, supporting clinicians in the choice of minor tranquillizer in this prevalent and help-seeking, clinically heterogeneous population.<\/jats:p>","DOI":"10.1007\/s00406-023-01680-0","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T11:01:41Z","timestamp":1692961301000},"page":"475-486","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Minor tranquillizers for short-term treatment of newly onset symptoms of anxiety and distress: a systematic review with network meta-analysis of randomized trials"],"prefix":"10.1007","volume":"274","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6437-0359","authenticated-orcid":false,"given":"Klaus","family":"Munkholm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Ussing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Brink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henriette","family":"Edemann-Callesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seng\u00fcl Sari","family":"Canbolat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristine S\u00f8gaard","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f8rn H.","family":"Ebdrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikkel Erik Juul","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casper","family":"Kierulf-Lassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gitte Krogh","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina Mai","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla Paludan","family":"Paulsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanett Friis","family":"Rohde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Tarp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lone","family":"Baandrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,25]]},"reference":[{"key":"1680_CR1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1600-0447.1990.tb01401.x","volume":"82","author":"M Albus","year":"1990","unstructured":"Albus M, Lecrubier Y, Maier W, Buller R, Rosenberg R, Hippius H (1990) Drug treatment of panic disorder: early response to treatment as a predictor of final outcome. Acta Psychiatr Scand 82:359\u2013365","journal-title":"Acta Psychiatr Scand"},{"key":"1680_CR2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/(SICI)1099-1077(199908)14:6<429::AID-HUP108>3.0.CO;2-3","volume":"14","author":"M Amore","year":"1999","unstructured":"Amore M, Magnani K, Cerisoli M, Casagrande C, Ferrari G (1999) Panic disorder. A long-term treatment study: fluoxetine vs imipramine. Hum Psychopharmacol Clin Exp 14:429\u2013434","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"1680_CR3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/(SICI)1099-1077(199607)11:4<293::AID-HUP771>3.0.CO;2-Z","volume":"11","author":"M Ansseau","year":"1996","unstructured":"Ansseau M, Bataille M, Briole G, de Nayer A, Fauchere PA, Ferrero F, Van Moffaert M (1996) Controlled comparison of tianeptine, alprazolam and mianserin in the treatment of adjustment disorders with anxiety and depression. Hum Psychopharmacol Clin Exp 11:293\u2013298","journal-title":"Hum Psychopharmacol Clin Exp"},{"issue":"Suppl 2","key":"1680_CR4","first-page":"S77","volume":"16","author":"D Bakish","year":"1993","unstructured":"Bakish D, Saxena BM, Bowen R, D\u2019Souza J (1993) Reversible monoamine oxidase-a inhibitors in panic disorder. Clin Neuropharmacol 16(Suppl 2):S77-82","journal-title":"Clin Neuropharmacol"},{"key":"1680_CR5","first-page":"CD011567","volume":"9","author":"I Bighelli","year":"2016","unstructured":"Bighelli I, Trespidi C, Castellazzi M, Cipriani A, Furukawa TA, Girlanda F, Guaiana G, Koesters M, Barbui C (2016) Antidepressants and benzodiazepines for panic disorder in adults. The Cochrane Database Syst Rev 9:CD011567","journal-title":"The Cochrane Database Syst Rev"},{"key":"1680_CR6","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00127-015-1129-8","volume":"51","author":"L Baandrup","year":"2016","unstructured":"Baandrup L, Kruse M (2016) Incident users of antipsychotics: who are they and how do they fare? Soc Psychiatry Psychiatr Epidemiol 51:505\u2013512","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"1680_CR7","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1192\/bjp.160.2.191","volume":"160","author":"Cncps","year":"1992","unstructured":"Cncps (1992) Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Cross-national collaborative panic study, second phase investigators. Brit J Psychiatry 160:191\u2013202 (discussion 202\u2013195)","journal-title":"Brit J Psychiatry"},{"key":"1680_CR8","unstructured":"Danish Health Authority (2022) National clinical recommendation on the use of mild tranquilizers"},{"key":"1680_CR9","unstructured":"Danish Health Authority (2021) National clinical recommendation on the use of mild tranquilizers - focused clinical question"},{"key":"1680_CR10","unstructured":"Danish Health Data Authority (2021) Skift i behandlingen af s\u00f8vnl\u00f8shed og angsttilstande over de seneste 10 \u00e5r"},{"key":"1680_CR11","unstructured":"Danish Health Data Authority (2018) Stadig f\u00e6rre langtidsbrugere af sovemedicin og angstd\u00e6mpende medicin. In:"},{"key":"1680_CR12","unstructured":"Danish Health Data Authority (2021) Tredobling i forbrug af det antipsykotiske middel quetiapin i lavdosis gennem de sidste 10 \u00e5r"},{"key":"1680_CR13","unstructured":"Danish Ministry of Health (2008) Vejledning om ordination af afh\u00e6ngighedsskabende l\u00e6gemidler"},{"key":"1680_CR14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2466\/pr0.1989.64.1.51","volume":"64","author":"D De Leo","year":"1989","unstructured":"De Leo D (1989) Treatment of adjustment disorders: a comparative evaluation. Psychol Rep 64:51\u201354","journal-title":"Psychol Rep"},{"key":"1680_CR15","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/030006059902700502","volume":"27","author":"S De Wit","year":"1999","unstructured":"De Wit S, Cremers L, Hirsch D, Zulian C, Clumeck N, Kormoss N (1999) Efficacy and safety of trazodone versus clorazepate in the treatment of hiv-positive subjects with adjustment disorders: a pilot study. J Int Med Res 27:223\u2013232","journal-title":"J Int Med Res"},{"key":"1680_CR16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00004850-198801000-00005","volume":"3","author":"JA Den Boer","year":"1988","unstructured":"Den Boer JA, Westenberg HG (1988) Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 3:59\u201374","journal-title":"Int Clin Psychopharmacol"},{"key":"1680_CR17","unstructured":"Emea EMA (2005) Scientific discussion from emea. Product name: Lyrica product no: Mea\/h\/c\/000546\/ii\/0004. In: EMEA"},{"key":"1680_CR18","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/bcpt.12347","volume":"116","author":"SI Eriksen","year":"2015","unstructured":"Eriksen SI, Bjerrum L (2015) Reducing prescriptions of long-acting benzodiazepine drugs in denmark: a descriptive analysis of nationwide prescriptions during a 10-year period. Basic Clin Pharmacol Toxicol 116:499\u2013502","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1680_CR19","first-page":"240","volume":"23","author":"DE Feltner","year":"2003","unstructured":"Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD, Liu-Dumaw M, Carter CM, Pande AC (2003) A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 23:240\u2013249","journal-title":"J Clin Psychopharmacol"},{"key":"1680_CR20","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, Alderson P, Glasziou P, Falck-Ytter Y, Schunemann HJ (2011) Grade guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol 64:395\u2013400","journal-title":"J Clin Epidemiol"},{"key":"1680_CR21","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods G, Cochrane Statistical Methods G (2011) The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928","journal-title":"BMJ"},{"key":"1680_CR22","volume-title":"Cochrane handbook for systematic reviews of interventions","year":"2019","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) (2019) Cochrane handbook for systematic reviews of interventions. John Wiley & Sons, Chichester"},{"key":"1680_CR23","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/wps.21010","volume":"21","author":"M Hojlund","year":"2022","unstructured":"Hojlund M, Andersen K, Ernst MT, Correll CU, Hallas J (2022) Use of low-dose quetiapine increases the risk of major adverse cardiovascular events: results from a nationwide active comparator-controlled cohort study. World Psychiatry 21:444\u2013451","journal-title":"World Psychiatry"},{"key":"1680_CR24","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.3209","volume":"4","author":"M Hojlund","year":"2021","unstructured":"Hojlund M, Lund LC, Andersen K, Correll CU, Hallas J (2021) Association of low-dose quetiapine and diabetes. JAMA Netw Open 4:e213209","journal-title":"JAMA Netw Open"},{"key":"1680_CR25","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1111\/bcp.15388","volume":"88","author":"M Hojlund","year":"2022","unstructured":"Hojlund M, Rasmussen L, Olesen M, Munk-Olsen T, Pottegard A (2022) Who prescribes quetiapine in denmark? Br J Clin Pharmacol 88:4224\u20134229","journal-title":"Br J Clin Pharmacol"},{"key":"1680_CR26","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catala-Lopez F, Gotzsche PC, Dickersin K, Boutron I, Altman DG, Moher D (2015) The prisma extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162:777\u2013784","journal-title":"Ann Intern Med"},{"key":"1680_CR27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/bcpt.13811","volume":"132","author":"M H\u00f8jlund","year":"2022","unstructured":"H\u00f8jlund M, Gudmundsson LS, Andersen JH, Saastamoinen LK, Zoega H, Skurtveit SO, Wastesson JW, Hallas J, Potteg\u00e5rd A (2022) Use of benzodiazepines and benzodiazepine-related drugs in the nordic countries between 2000 and 2020. Basic Clin Pharmacol Toxicol 132:60\u201370","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1680_CR28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/imj.12315","volume":"44","author":"MM Islam","year":"2014","unstructured":"Islam MM, Conigrave KM, Day CA, Nguyen Y, Haber PS (2014) Twenty-year trends in benzodiazepine dispensing in the australian population. Intern Med J 44:57\u201364","journal-title":"Intern Med J"},{"key":"1680_CR29","volume":"179","author":"MB Jorgensen","year":"2017","unstructured":"Jorgensen MB, Videbech P, Osler M (2017) benzodiazepines still play a role in modern psychiatric therapy. Ugeskr Laeger 179:V04170274","journal-title":"Ugeskr Laeger"},{"key":"1680_CR30","first-page":"5","volume":"44","author":"A Khan","year":"2011","unstructured":"Khan A, Atkinson S, Mezhebovsky I, She F, Leathers T, Pathak S (2011) Extended release quetiapine fumarate (quetiapine xr) as adjunct therapy in patients with generalized anxiety disorder and a history of inadequate treatment response: a randomized, double-blind study. Psychopharmacol Bull 44:5\u201331","journal-title":"Psychopharmacol Bull"},{"issue":"Suppl 1","key":"1680_CR31","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1007\/PL00014163","volume":"249","author":"MB Kruger","year":"1999","unstructured":"Kruger MB, Dahl AA (1999) The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder. Eur Arch Psychiatry Clin Neurosci 249(Suppl 1):S19-24","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1680_CR32","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/pds.4551","volume":"27","author":"T Kurko","year":"2018","unstructured":"Kurko T, Saastamoinen LK, Tuulio-Henriksson A, Taiminen T, Tiihonen J, Airaksinen M, Hietala J (2018) Trends in the long-term use of benzodiazepine anxiolytics and hypnotics: a national register study for 2006 to 2014. Pharmacoepidemiol Drug Saf 27:674\u2013682","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1680_CR33","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.eurpsy.2015.09.003","volume":"30","author":"TA Kurko","year":"2015","unstructured":"Kurko TA, Saastamoinen LK, Tahkapaa S, Tuulio-Henriksson A, Taiminen T, Tiihonen J, Airaksinen MS, Hietala J (2015) Long-term use of benzodiazepines: definitions, prevalence and usage patterns - a systematic review of register-based studies. Eur Psychiatry 30:1037\u20131047","journal-title":"Eur Psychiatry"},{"key":"1680_CR34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/hup.470050209","volume":"5","author":"U Lepola","year":"1990","unstructured":"Lepola U, Heikkinen H, Rimon RRP (1990) Clinical evaluation of alprazolam in patients with panic disorder; a double-blind comparison with imipramine. Hum Psychopharmacol 5:159\u2013163","journal-title":"Hum Psychopharmacol"},{"key":"1680_CR35","first-page":"8","volume":"46","author":"R Li","year":"2016","unstructured":"Li R, Wu R, Chen J, Kemp DE, Ren M, Conroy C, Chan P, Serrano MB, Ganocy SJ, Calabrese JR, Gao K (2016) A randomized, placebo-controlled pilot study of quetiapine-xr monotherapy or adjunctive therapy to antidepressant in acute major depressive disorder with current generalized anxiety disorder. Psychopharmacol Bull 46:8\u201323","journal-title":"Psychopharmacol Bull"},{"key":"1680_CR36","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1001\/archpsyc.49.4.290","volume":"49","author":"MR Liebowitz","year":"1992","unstructured":"Liebowitz MR, Schneier F, Campeas R, Hollander E, Hatterer J, Fyer A, Gorman J, Papp L, Davies S, Gully R et al (1992) Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry 49:290\u2013300","journal-title":"Arch Gen Psychiatry"},{"key":"1680_CR37","first-page":"1","volume":"80","author":"L Lin","year":"2017","unstructured":"Lin L, Zhang J, Hodges JS, Chu H (2017) Performing arm-based network meta-analysis in r with the pcnetmeta package. J Stat Softw 80:1\u201325","journal-title":"J Stat Softw"},{"key":"1680_CR38","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.4088\/JCP.v63n1112","volume":"63","author":"PM Llorca","year":"2002","unstructured":"Llorca PM, Spadone C, Sol O, Danniau A, Bougerol T, Corruble E, Faruch M, Macher JP, Sermet E, Servant D (2002) Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. J Clin Psychiatry 63:1020\u20131027","journal-title":"J Clin Psychiatry"},{"key":"1680_CR39","unstructured":"MAGIC Evidence Ecosystem Fundation (2022) Magicapp"},{"key":"1680_CR40","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/YIC.0b013e32834d9f49","volume":"27","author":"C Merideth","year":"2012","unstructured":"Merideth C, Cutler AJ, She F, Eriksson H (2012) Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study. Int Clin Psychopharmacol 27:40\u201354","journal-title":"Int Clin Psychopharmacol"},{"key":"1680_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1461145712000065","volume":"16","author":"D Michelson","year":"2013","unstructured":"Michelson D, Hargreaves R, Alexander R, Ceesay P, Hietala J, Lines C, Reines S (2013) Lack of efficacy of l-759274, a novel neurokinin 1 (substance p) receptor antagonist, for the treatment of generalized anxiety disorder. Int J Neuropsychopharmacol 16:1\u201311","journal-title":"Int J Neuropsychopharmacol"},{"key":"1680_CR42","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00004714-200102000-00011","volume":"21","author":"HJ Moller","year":"2001","unstructured":"Moller HJ, Volz HP, Reimann IW, Stoll KD (2001) Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol 21:59\u201365","journal-title":"J Clin Psychopharmacol"},{"key":"1680_CR43","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/hup.757","volume":"21","author":"N Nguyen","year":"2006","unstructured":"Nguyen N, Fakra E, Pradel V, Jouve E, Alquier C, Le Guern ME, Micallef J, Blin O (2006) Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice. Hum Psychopharmacol 21:139\u2013149","journal-title":"Hum Psychopharmacol"},{"key":"1680_CR44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","volume":"17","author":"A Nikolakopoulou","year":"2020","unstructured":"Nikolakopoulou A, Higgins JPT, Papakonstantinou T, Chaimani A, Del Giovane C, Egger M, Salanti G (2020) Cinema: an approach for assessing confidence in the results of a network meta-analysis. PLoS Med 17:e1003082","journal-title":"PLoS Med"},{"key":"1680_CR45","first-page":"349","volume":"57","author":"R Noyes Jr","year":"1996","unstructured":"Noyes R Jr, Burrows GD, Reich JH, Judd FK, Garvey MJ, Norman TR, Cook BL, Marriott P (1996) Diazepam versus alprazolam for the treatment of panic disorder. J Clin Psychiatry 57:349\u2013355","journal-title":"J Clin Psychiatry"},{"key":"1680_CR46","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/jts.22295","volume":"31","author":"ML O\u2019Donnell","year":"2018","unstructured":"O\u2019Donnell ML, Metcalf O, Watson L, Phelps A, Varker T (2018) A systematic review of psychological and pharmacological treatments for adjustment disorder in adults. J Trauma Stress 31:321\u2013331","journal-title":"J Trauma Stress"},{"key":"1680_CR47","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamapsychiatry.2014.1763","volume":"72","author":"M Olfson","year":"2015","unstructured":"Olfson M, King M, Schoenbaum M (2015) Benzodiazepine use in the united states. JAMA Psychiat 72:136\u2013142","journal-title":"JAMA Psychiat"},{"key":"1680_CR48","volume":"18","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hrobjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The prisma 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med 18:e1003583","journal-title":"PLoS Med"},{"key":"1680_CR49","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1176\/appi.ajp.160.3.533","volume":"160","author":"AC Pande","year":"2003","unstructured":"Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, Londborg PD, Bielski RJ, Zimbroff DL, Davidson JR, Liu-Dumaw M (2003) Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 160:533\u2013540","journal-title":"Am J Psychiatry"},{"key":"1680_CR50","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/10401230701866870","volume":"20","author":"NS Philip","year":"2008","unstructured":"Philip NS, Mello K, Carpenter LL, Tyrka AR, Price LH (2008) Patterns of quetiapine use in psychiatric inpatients: an examination of off-label use. Ann Clin Psychiatry 20:15\u201320","journal-title":"Ann Clin Psychiatry"},{"key":"1680_CR51","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1177\/030006059902700602","volume":"27","author":"D Razavi","year":"1999","unstructured":"Razavi D, Kormoss N, Collard A, Farvacques C, Delvaux N (1999) Comparative study of the efficacy and safety of trazodone versus clorazepate in the treatment of adjustment disorders in cancer patients: a pilot study. J Int Med Res 27:264\u2013272","journal-title":"J Int Med Res"},{"key":"1680_CR52","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1001\/archpsyc.62.9.1022","volume":"62","author":"K Rickels","year":"2005","unstructured":"Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, Tobias K, Brock JD, Zornberg GL, Pande AC (2005) Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 62:1022\u20131030","journal-title":"Arch Gen Psychiatry"},{"key":"1680_CR53","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1600-0447.1997.tb09660.x","volume":"95","author":"P Rocca","year":"1997","unstructured":"Rocca P, Fonzo V, Scotta M, Zanalda E, Ravizza L (1997) Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 95:444\u2013450","journal-title":"Acta Psychiatr Scand"},{"key":"1680_CR54","unstructured":"R\u00fccker G, Krahn U, K\u00f6nig J, Efthimiou O, Davies A, Papakonstantinou T, Schwarzer G (2022) Netmeta: network meta-analysis using frequentist methods. In: R package version 25-0"},{"key":"1680_CR55","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","volume":"15","author":"G R\u00fccker","year":"2015","unstructured":"R\u00fccker G, Schwarzer G (2015) Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol 15:58","journal-title":"BMC Med Res Methodol"},{"key":"1680_CR56","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/archpsyc.1993.01820130053009","volume":"50","author":"E Schweizer","year":"1993","unstructured":"Schweizer E, Rickels K, Weiss S, Zavodnick S (1993) Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Arch Gen Psychiatry 50:51\u201360","journal-title":"Arch Gen Psychiatry"},{"key":"1680_CR57","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman A, editors (2013) Grade handbook for grading quality of evidence and strength of recommendations. Updated october 2013., Available from guidelinedevelopment.org\/handbook"},{"key":"1680_CR58","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jclinepi.2008.10.009","volume":"62","author":"BJ Shea","year":"2009","unstructured":"Shea BJ, Hamel C, Wells GA, Bouter LM, Kristjansson E, Grimshaw J, Henry DA, Boers M (2009) Amstar is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol 62:1013\u20131020","journal-title":"J Clin Epidemiol"},{"key":"1680_CR59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002635","volume":"15","author":"A Sidorchuk","year":"2018","unstructured":"Sidorchuk A, Isomura K, Molero Y, Hellner C, Lichtenstein P, Chang Z, Franck J, Fern\u00e1ndez de la Cruz L, Mataix-Cols D (2018) Benzodiazepine prescribing for children, adolescents, and young adults from 2006 through 2013: a total population register-linkage study. PLoS Med 15:e1002635","journal-title":"PLoS Med"},{"key":"1680_CR60","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0140-6736(18)31793-8","volume":"393","author":"A Slee","year":"2019","unstructured":"Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N (2019) Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet 393:768\u2013777","journal-title":"Lancet"},{"key":"1680_CR61","doi-asserted-by":"crossref","first-page":"8391637","DOI":"10.1155\/2017\/8391637","volume":"2017","author":"MF Song","year":"2017","unstructured":"Song MF, Hu LL, Liu WJ, Liu Y, Tao XY, Wang TT, Wang SD, Zhang L, Zhang YH (2017) Modified suanzaorentang had the treatment effect for generalized anxiety disorder for the first 4 weeks of paroxetine medication: a pragmatic randomized controlled study. Evid Based Complement Alternat Med 2017:8391637","journal-title":"Evid Based Complement Alternat Med"},{"key":"1680_CR62","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1056\/NEJMra1611832","volume":"376","author":"M Soyka","year":"2017","unstructured":"Soyka M (2017) Treatment of benzodiazepine dependence. N Engl J Med 376:1147\u20131157","journal-title":"N Engl J Med"},{"key":"1680_CR63","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s12325-015-0176-6","volume":"32","author":"DJ Stein","year":"2015","unstructured":"Stein DJ (2015) Etifoxine versus alprazolam for the treatment of adjustment disorder with anxiety: a randomized controlled trial. Adv Ther 32:57\u201368","journal-title":"Adv Ther"},{"key":"1680_CR64","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.euroneuro.2017.02.007","volume":"27","author":"DJ Stein","year":"2017","unstructured":"Stein DJ, Ahokas A, Jarema M, Avedisova AS, Vavrusova L, Chaban O, Gruget C, Olivier V, Picarel-Blanchot F, de Bodinat C (2017) Efficacy and safety of agomelatine (10 or 25 mg\/day) in non-depressed out-patients with generalized anxiety disorder: a 12-week, double-blind, placebo-controlled study. Eur Neuropsychopharmacol 27:526\u2013537","journal-title":"Eur Neuropsychopharmacol"},{"key":"1680_CR65","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/JCP.0b013e318184ff5b","volume":"28","author":"DJ Stein","year":"2008","unstructured":"Stein DJ, Ahokas AA, de Bodinat C (2008) Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 28:561\u2013566","journal-title":"J Clin Psychopharmacol"},{"key":"1680_CR66","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.euroneuro.2008.01.004","volume":"18","author":"DJ Stein","year":"2008","unstructured":"Stein DJ, Baldwin DS, Baldinetti F, Mandel F (2008) Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. Eur Neuropsychopharmacol 18:422\u2013430","journal-title":"Eur Neuropsychopharmacol"},{"key":"1680_CR67","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1089\/cap.2017.0140","volume":"28","author":"SM Tahkapaa","year":"2018","unstructured":"Tahkapaa SM, Saastamoinen L, Airaksinen M, Tuulio-Henriksson A, Aalto-Setala T, Kurko T (2018) Decreasing trend in the use and long-term use of benzodiazepines among young adults. J Child Adolesc Psychopharmacol 28:279\u2013284","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1680_CR68","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.19029","volume":"3","author":"H Taipale","year":"2020","unstructured":"Taipale H, Sarkila H, Tanskanen A, Kurko T, Taiminen T, Tiihonen J, Sund R, Tuulio-Henriksson A, Saastamoinen L, Hietala J (2020) Incidence of and characteristics associated with long-term benzodiazepine use in finland. JAMA Netw Open 3:e2019029","journal-title":"JAMA Netw Open"},{"key":"1680_CR69","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/00004714-199004000-00006","volume":"10","author":"CB Taylor","year":"1990","unstructured":"Taylor CB, Hayward C, King R, Ehlers A, Margraf J, Maddock R, Clark D, Roth WT, Agras WS (1990) Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double-blind, placebo-controlled trial. J Clin Psychopharmacol 10:112\u2013118","journal-title":"J Clin Psychopharmacol"},{"key":"1680_CR70","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12630-008-9007-4","volume":"56","author":"L Thabane","year":"2009","unstructured":"Thabane L, Thomas T, Ye C, Paul J (2009) Posing the research question: not so simple. Can J Anaesth 56:71\u201379","journal-title":"Can J Anaesth"},{"key":"1680_CR71","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1186\/s12889-020-08984-z","volume":"20","author":"F Torres-Bondia","year":"2020","unstructured":"Torres-Bondia F, de Batlle J, Galv\u00e1n L, Buti M, Barb\u00e9 F, Pi\u00f1ol-Ripoll G (2020) Trends in the consumption rates of benzodiazepines and benzodiazepine-related drugs in the health region of lleida from 2002 to 2015. BMC Public Health 20:818","journal-title":"BMC Public Health"},{"key":"1680_CR72","unstructured":"van Valkenhoef G, Kuiper J (2021) Gemtc: network meta-analysis using bayesian methods. In: R package version 10-1"},{"key":"1680_CR73","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0924-977X(92)90032-4","volume":"2","author":"IM van Vliet","year":"1992","unstructured":"van Vliet IM, den Boer JA, Westenberg HG (1992) Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective mao-a inhibitor. Eur Neuropsychopharmacol 2:21\u201329","journal-title":"Eur Neuropsychopharmacol"},{"key":"1680_CR74","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4088\/JCP.v58n0405","volume":"58","author":"IM van Vliet","year":"1997","unstructured":"van Vliet IM, den Boer JA, Westenberg HG, Pian KL (1997) Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. J Clin Psychiatry 58:164\u2013168","journal-title":"J Clin Psychiatry"},{"key":"1680_CR75","first-page":"167","volume":"46","author":"M Versiani","year":"1997","unstructured":"Versiani M, Nardi AE, Figueira I, Mendlowicz M, Marques C (1997) Double-blind placebo controlled trial with bromazepam in social phobia. J Bras Psiquiatr 46:167\u2013171","journal-title":"J Bras Psiquiatr"},{"key":"1680_CR76","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1192\/bjp.161.3.353","volume":"161","author":"M Versiani","year":"1992","unstructured":"Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, Amrein R (1992) Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br J Psychiatry 161:353\u2013360","journal-title":"Br J Psychiatry"},{"key":"1680_CR77","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1017\/neu.2020.6","volume":"32","author":"T Williams","year":"2020","unstructured":"Williams T, McCaul M, Schwarzer G, Cipriani A, Stein DJ, Ipser J (2020) Pharmacological treatments for social anxiety disorder in adults: a systematic review and network meta-analysis. Acta Neuropsychiatr 32:169\u2013176","journal-title":"Acta Neuropsychiatr"},{"key":"1680_CR78","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.896","volume":"10","author":"A Woods","year":"2022","unstructured":"Woods A, Begum M, Gonzalez-Chica D, Bernardo C, Hoon E, Stocks N (2022) Long-term benzodiazepines and z-drug prescribing in australian general practice between 2011 and 2018: a national study. Pharmacol Res Perspect 10:e00896","journal-title":"Pharmacol Res Perspect"},{"key":"1680_CR79","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/schbul\/sbac001","volume":"48","author":"H Wu","year":"2022","unstructured":"Wu H, Siafis S, Hamza T, Schneider-Thoma J, Davis JM, Salanti G, Leucht S (2022) Antipsychotic-induced weight gain: dose-response meta-analysis of randomized controlled trials. Schizophr Bull 48:643\u2013654","journal-title":"Schizophr Bull"},{"key":"1680_CR80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/neu.2022.36","volume":"35","author":"SD \u00d8stergaard","year":"2022","unstructured":"\u00d8stergaard SD, Rohde C (2022) The use of low-dose quetiapine does not necessarily increase the risk of major adverse cardiovascular events. Acta Neuropsychiatr 35:1\u20135","journal-title":"Acta Neuropsychiatr"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-023-01680-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-023-01680-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-023-01680-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T21:28:45Z","timestamp":1729978125000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-023-01680-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1680"],"URL":"https:\/\/doi.org\/10.1007\/s00406-023-01680-0","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,25]]},"assertion":[{"value":"1 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Klaus Munkholm, Anja Ussing, Maria Brink, Henriette Edemann Callesen, Seng\u00fcl Sari Canbolat, Robin Christensen, Kristine S\u00f8gaard Dahl, Mikkel Erik Juul Jensen, Casper Kierulf Lassen, Gitte Krogh Madsen, Sabrina Mai Nielsen, Camilla Paludan Paulsen, Jeanett Friis Rohde, Simon Tarp and Lone Baandrup report no conflict of interest. Bj\u00f8rn H. Ebdrup has received lecture fees and\/or is part of Advisory Boards of Bristol-Myers Squibb, Eli Lilly and Company, Janssen-Cilag, Otsuka Pharma Scandinavia AB, Takeda Pharmaceutical Company, Boehringer Ingelheim, and Lundbeck Pharma A\/S.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}